Concepedia

Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction

Seiji Kawashita, Koichi Aoyagi, Hiroshi Yamanaka, Rie Hantani, Shiori Naruoka, Atsuo Tanimoto, Yuji Hori, Yukiyo Toyonaga, Kyoko Fukushima, Susumu Miyazaki,

Bioorganic & Medicinal Chemistry Letters · 2019 · 22 citations · 14 references

DOIFull text

Open access

Concepts

References

14

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz et al. · Nature · 2014 · 5.3K citations

, , +16

<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates

Changyu Wang, Kent Thudium, Minhua Han et al. · Cancer Immunology Research · 2014 · 592 citations

, , +17

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

Krzysztof M. Żak, Radosław Kitel, Sara Przetocka et al. · Structure · 2015 · 526 citations · Full text

, , +13

The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors

David Yin-wei Lin, Yoshimasa Tanaka, Masashi Iwasaki et al. · Proceedings of the National Academy of Sciences · 2008 · 457 citations · Full text

, , +17

Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)

Krzysztof M. Żak, P. Grudnik, Katarzyna Guzik et al. · Oncotarget · 2016 · 423 citations · Full text

, , +17